LabStyle Innovations Corp. (Dario™) — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014; filed August 14, 2014. The filing names LabStyle Innovations Corp., not Dariohealth Corp. It describes Dario™ as a pre-revenue mobile diabetes-management product.
Financial performance and position
| Metric (USD thousands, except per-share data) | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Ramp-up manufacturing costs / gross loss | $605 | $0 | $1,026 | $0 |
| Operating expenses | $2,998 | $3,596 | $5,245 | $6,672 |
| Operating loss | $3,603 | $3,596 | $6,271 | $6,672 |
| Net loss | $3,254 | $5,286 | $6,238 | $10,513 |
| Basic loss per share | $0.14 | $0.29 | $0.28 | $0.63 |
- Margins: Not meaningful with no recognized revenue; manufacturing ramp-up costs generated gross losses.
- Cash flow: Six-month operating cash use was $4,418, investing cash use $130, and financing inflow $4,104. Cash and equivalents declined $444 to $1,819 from year-end 2013.
- Liquidity and liabilities: Current assets were $2,362 and current liabilities $1,776 at June 30, 2014. The company reported a $5,379 warrant liability, total assets of $3,402, and stockholders’ deficit of $3,753. No conventional borrowings are identified in the provided filing text.
- Equity funding: A February private placement and exercises of options and warrants generated $4,104 net cash in the first half. Shares outstanding were 23,013,889 at June 30; 25,498,305 were outstanding as of August 13.
Changes versus prior year
- Six-month net loss improved by $4,275, primarily reflecting lower warrant revaluation expense and lower general and administrative costs, partly offset by higher research and development and new manufacturing ramp-up costs.
- Operating cash use increased from $3,021 to $4,418, while financing proceeds declined from $10,146 to $4,104.
- Operating expenses fell year over year for both the quarter and half-year overall; six-month R&D rose to $2,440 from $2,091, while marketing/pre-production and G&A declined.
- The company began a soft commercial launch and shipped product, but recorded no revenue. Management said revenue recognition awaited evidence of consistent distributor payments and a reasonably estimable warranty-return provision.
Outlook, developments, and risks
- Management estimated available liquidity would support planned activity only into October 2014 and said substantial near-term financing was needed. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern; additional funding and sufficient initial sales were not assured.
- Plans, contingent on funding, included expanding the soft launch, scaling manufacturing and distribution, further product development, and pursuing U.S. regulatory approval. The company expected an FDA response to its 510(k) application later in 2014; no firm financial guidance was provided.
- Commercial/regulatory milestones cited included European CE marking, reimbursement coverage in Italy and the UK nations for strips and lancets effective September 1, 2014, and post-quarter Israel approval and an Android app release in selected markets.
- After quarter-end, the February financing’s reset provision resulted in issuance of 2,484,416 adjustment shares on July 2, based on an approximately $0.89 reset price, and triggered additional warrant adjustments. The filing warns of further potential dilution, possible pressure on the share price, and impairment of future financing ability.
- Warrants are carried as liabilities and remeasured at fair value; the six-month period included $538 of warrant revaluation income, a material non-cash item. The filing also reports no legal proceedings and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Whether the company secured financing after the stated October 2014 liquidity horizon, and how that affected its going-concern position.
- Whether distributor sales converted into recognized revenue, cash collections, and returns/warranty obligations.
- The full dilution and potential future share or warrant issuances under the private-placement reset and anti-dilution terms.
- FDA review outcome, commercialization progress, and whether reimbursement and distribution arrangements translated into sales.
- The warrant liability’s valuation assumptions and sensitivity, given its significant effect on reported earnings and balance-sheet liabilities.